Key clinical point: Patients with HIV who are treated with nivolumab, a programmed death-1 (PD-1) inhibitor, appear to have similar safety and efficacy outcomes compared with HIV-negative patients treated with the same agent.
Major finding: No immune-related adverse events or deaths due to drug toxicity occurred.
Study details: A retrospective analysis of 20 patients with HIV who received nivolumab immunotherapy.
Disclosures: Jean-Philippe Spano, principal investigator, disclosed relationships with Gilead, Roche, BMS, and others.
Gobert et al. ESMO 2018, Abstract 1213P_PR.